Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients.
about
Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD PatientsThe gut microbiota and host health: a new clinical frontierClassical and recent advances in the treatment of inflammatory bowel diseases16S rRNA gene sequencing and healthy reference ranges for 28 clinically relevant microbial taxa from the human gut microbiome.Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis.Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease.Gut microbiota in multiple sclerosis: possible influence of immunomodulatorsDeviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBDThe Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond.Two distinct metacommunities characterize the gut microbiota in Crohn's disease patients.Gut microbiota differs between children with Inflammatory Bowel Disease and healthy siblings in taxonomic and functional composition: a metagenomic analysis.The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.Low-complexity microbiota in the duodenum of children with newly diagnosed ulcerative colitis.Serum bacterial toxins are related to the progression of inflammatory bowel disease.The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis.Immunomodulation and effects on microbiota after in ovo administration of chicken cathelicidin-2.
P2860
Q26750985-44295756-5510-48D9-8009-DD04A9B96787Q26785649-3F4C76D5-EB54-49A4-9F48-FDF95D8BD9AFQ26861725-5C4C7E40-37F0-4BC6-884A-91CBBB8FCF1CQ33632346-A3B547FC-A89F-476E-B5C1-9E9E3D9BDFDDQ34746752-69A1FFDD-0E10-4F61-80D5-DBE5258462CAQ35271319-97025667-0235-40C9-A957-F8BD6E5AEFD3Q35578319-01F2EA70-DC50-4805-8B09-43D391439C31Q35631365-498C50B5-243B-4204-8B2C-FC5715076867Q38676932-EF883D66-95F8-4397-A4CF-4B8922A90845Q38706536-AE32A267-A337-4218-BCA6-F75D1E47EA70Q39049156-EBD63B31-2DDB-4B8E-9027-D00F9C847D0BQ46279754-E0FB2E54-FB19-45CE-8F31-AD7909BBA130Q46280371-ECCD8FA9-CBB5-4CD5-BE7B-73E0E835F03AQ49997104-07BCF0D5-9EBB-4213-92D0-32C8F1D0C269Q50699253-AF030FA8-EC3C-452D-803D-83531238AC45Q55325660-D8ABDF16-F066-4EDA-B2FE-1D20669A7656
P2860
Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Dominant fecal microbiota in n ...... matory bowel disease patients.
@ast
Dominant fecal microbiota in n ...... matory bowel disease patients.
@en
type
label
Dominant fecal microbiota in n ...... matory bowel disease patients.
@ast
Dominant fecal microbiota in n ...... matory bowel disease patients.
@en
prefLabel
Dominant fecal microbiota in n ...... matory bowel disease patients.
@ast
Dominant fecal microbiota in n ...... matory bowel disease patients.
@en
P2093
P2860
P50
P356
P1476
Dominant fecal microbiota in n ...... matory bowel disease patients.
@en
P2093
Felix Chinweije Nwosu
Gøri Perminow
Lill Therese Thorkildsen
Petr Ricanek
Stephan Brackmann
P2860
P304
P356
10.1155/2013/636785
P577
2013-11-17T00:00:00Z